A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium.
Saved in:
| Title: | A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium. |
|---|---|
| Authors: | Yanagisawa T; Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan. t.yanagisawa.jikei@gmail.com.; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. t.yanagisawa.jikei@gmail.com., Mori K; Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan.; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Kawada T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Katayama S; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Tsujino T; Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan., Maenosono R; Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan., Toyoda S; Department of Urology, Faculty of Medicine, Kindai University, Higashi-osaka, Japan., Nukaya T; Department of Urology, Fujita-Health University School of Medicine, Toyoake, Japan., Morinaka H; Department of Urology, Kawasaki Medical School, Kurashiki, Japan., Tamura K; Department of Urology, Hamamatsu Medical University, Hamamatsu, Japan., Fukuokaya W; Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan., Urabe F; Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan., Murakami M; Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan., Bekku K; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Takahara K; Department of Urology, Fujita-Health University School of Medicine, Toyoake, Japan., Fujita K; Department of Urology, Faculty of Medicine, Kindai University, Higashi-osaka, Japan., Azuma H; Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan., Araki M; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Inamoto T; Department of Urology, Hamamatsu Medical University, Hamamatsu, Japan., Komura K; Department of Urology, Kawasaki Medical School, Kurashiki, Japan., Kimura T; Department of Urology, The Jikei University School of Medicine, Nishi-Shimbashi, Japan. |
| Corporate Authors: | JK-FOOT study group |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Feb 25; Vol. 75 (3). Date of Electronic Publication: 2026 Feb 25. |
| Publication Type: | Journal Article; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-025-04288-6 |
